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OBJECTIVE: In 2002, Maine’s Tobacco HelpLine began offer-
ing free nicotine replacement therapy (NRT), including patch
and/or gum, to adult smokers who were uninsured without NRT
beneﬁts. A study was conducted in 2005 to assess knowledge,
utilization patterns, short-term outcomes, and satisfaction
among a sample of Maine Tobacco HelpLine callers who re-
ceived this free NRT from any Maine pharmacy. METHODS:
Telephone surveys were conducted in June-July 2005 among 541
eligible HelpLine callers authorized for NRT between February-
March 2005. There were 393 completed interviews, for a 73%
response rate. Descriptive analyses and Chi-Square tests were
conducted using SPSS and SAS, including tests for signiﬁcant
differences by demographic variables and NRT utilization pat-
terns. RESULTS: Half of study respondents were aware of avail-
able free NRT prior to calling the HelpLine, and among them
95% indicated that NRT at least somewhat inﬂuenced their
decision to contact the HelpLine. Most callers were very satisﬁed
(88%) and reported that this process was ‘very helpful’ in their
quit attempt (66%). Almost all respondents picked up NRT
(99%), had no problems obtaining it (91%), and quit for at least
24 hours since calling the HelpLine (92%). Among those who
quit for at least 24 hours, 95% used NRT; but, 28% reported
stopping and starting NRT use and almost 40% reported side
effects, most commonly skin reactions or abnormal dreams. Chi-
square tests reported a signiﬁcant difference in side effects by age,
with more side effects among younger respondents. When sur-
veyed, 50% of respondents reported abstinence from smoking,
which signiﬁcantly differed by NRT duration; smoking during
NRT use; and timing of NRT use. CONCLUSION: Providing
free NRT through this state-supported program encouraged
smokers to contact the Maine Tobacco HelpLine and use avail-
able NRT, demonstrating a valuable opportunity for quit lines to
provide NRT access and increase demand among motivated
smokers.
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A STATISTICAL LOOK AT COPD
Cerrito PB,Augustus P
University of Louisville, Louisville, KY, USA
OBJECTIVE: The purpose of this paper is to take an analytical
view of the diagnosis and procedures that most frequently occur
with Chronic Obstructive Pulmonary Disease (COPD) patients
when they are admitted to the hospital. METHODS: The data
was collected from the National Inpatient Sample (NIS); they
were analyzed using the SAS Program Enterprise Guide 4. The
data were from over 32,000 patients that were diagnosed with
some type of COPD using a 10% sample from 2004. Some of the
variables examined were: the age, the length of stay, mortality
rates, total charges, and the diagnostic, and procedure codes for
the patients. In analyzing the data, codes were compressed to
ﬁlter the top 20 principle diagnosis codes, the top 20 procedure
codes, and the top twenty DRG codes. RESULTS: The results of
the data analysis show that there are many different principal
diagnoses, procedures, and DRG’s used when patients come to
the hospital with COPD. The highest principal diagnosis is
COPD and bronchiectasis, the top procedure is classiﬁed as other
vascular catheterization, and the top DRG in effect on the dis-
charge date is COPD. The results also show that 5% of the
patients died while they were in the hospital. The total charges
for the patients show that the majority of the patients’ total
charges were less than $10,000. Logistic regression showed that
mortality is directly related to these diagnostic and procedure
codes. CONCLUSION: More research on COPD is necessary.
COPD is the fourth leading cause of death in the US, but there is
virtually no research on the disease. The analysis of this dataset
shows that the knowledge of this disease is limited and more
research must be conducted.
PRS36
FACTORS ASSOCIATEDWITH ANTIHISTAMINE PRESCRIBING
IN ASTHMA INTHE UNITED STATES IN 2005
Parikh K, Li C, Martin BC
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OBJECTIVE: Although antihistamines do not have an on-label
indication for asthma, previous study showed increased prescrib-
ing in asthma by physicians. This study examined patient and
physician predictors of obtaining an antihistamine for asthma in
the absence of allergic diseases in 2005. METHODS: Ofﬁce-
based physician visits or outpatient visits by patients with asthma
were selected from the 2005 National Ambulatory Medical Care
Survey and the National Hospital Ambulatory Medical Care
Survey. Asthma was deﬁned by either a diagnosis code of asthma
(ICD-9-CM: 493.xx), a reason-for-visit code of asthma (2625.0),
or afﬁrmative answer to a question asking if patients have asthma
irrespective of the diagnosis. Visits with concomitant allergic
diseases indicated for antihistamines were excluded. The study
applied multivariate logistic regression analysis in Stata 9 to take
into account of the complex survey design. RESULTS: In 2005,
11% of the 54.3 millions asthma visits had an antihistamine
prescribed. During ofﬁce-based physician visits, females (OR:
1.25; 95%-CI: 1.07–2.02), patients prescribed leukotriene recep-
tor antagonists (LRTA) (OR: 2.94; 95%-CI: 1.33–6.50), or short
acting beta agonists (SABA) (OR: 2.37; 95%-CI: 1.24–4.53),
were more likely to receive an antihistamine prescription. Physi-
cians in Metropolitan Status Area (MSA) (OR: 2.23; 95%-CI:
1.03- 4.85) were more likely to prescribe antihistamine in
asthma. But those with access to electronic medical records
(EMR) (OR: 0.36; CI: 0.15–0.88) were less likely to do so. Only
LRTA (OR: 5.27; 95%-CI: 2.49–11.12), MSA (OR 9.01; 95%-
CI: 2.13–38.03) and EMR (OR: 0.27; 95%-CI: 0.08–0.88) were
signiﬁcant predictors for antihistamine prescribing in outpatient
department. However, asthma patients treated by their primary
care physicians were more likely to receive an antihistamine (OR:
2.9; 95%-CI: 1.45–5.80). CONCLUSION: Signiﬁcant disparities
in patient and physician characteristics were identiﬁed for
antihistamine prescribing in asthma. Results also indicate that
antihistamines were used as a complement for long-term asthma
management.
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OBJECTIVE: Medication possession ratios (MPRs) can be mis-
leading as an indicator of adherence, especially where several
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medications for the same indication are used concurrently. We
investigated whether concurrent utilization of controller asthma
medications in patients switching therapies differs between con-
troller medication classes and whether it may lead to signiﬁcant
biases in observed patterns of medication possession and inap-
propriate claims for long-term patient adherence. METHODS:
We used MPRs as a proxy measure of adherence to asthma
controller medications. Asthma controller utilization patterns
were investigated using the Pharmetrics Managed Care database
for the period April 2003 to March 2006. Asthma patients who
were exclusively on two of three major controller groups were
identiﬁed: inhaled corticosteroids (ICSs), ﬂuticasone/salmeterol
(FS), and leukotriene modiﬁers (LTMs). MPRs were calculated
for days of concurrent possession (DCPs) between last and ﬁrst
prescription recorded, as well as the proportion of days that were
covered by concurrent controller possession (CCPs). RESULTS:
Overall for the study population (n = 7260), 1328 patients had
prescriptions for LTMs and ICSs; 4871 for LTMs and FS; and
1061 for ICSs and FS. The mean CCPs were highest for persons
reporting prescriptions for both LTMs and FS (0.224). Lowest
CCP was for ICS and FS (0.023). DCP over the 3-year observa-
tion period was highest for persons with LTMs and FS (0.152 or
166 days) and lowest for those with ICSs and FS (0.009 or 10
days). CONCLUSION: The analysis points to a signiﬁcant
number of asthma patients using LTMs concurrently with
another controller medication. This occurs despite the lack of
clinical evidential support for concurrent utilization over an
extended period. Estimates of MPRs for controller therapies
based on prescription counts need to be corrected for concurrent
medication usage to avoid overstating therapy adherence.
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OBJECTIVE: To assess the correlation between health care uti-
lization after diagnosis of chronic obstructive pulmonary disease
(COPD) and controller therapies prescribed during the ﬁrst year
after diagnosis. METHODS: A cohort of 991 patients with initial
diagnosis of COPD between January 1, 2003 and December 31,
2004 were constructed from the Lovelace Patient Database.
Inclusion criteria included: ﬁrst diagnosis of COPD (ICD-9CM
491, 492, or 496), >1 year of pre and post-diagnosis observation,
and >1 pharmacy claim. Ethnicity was estimated using the
GUESS (Generally Useful Ethnicity Search System) program. Use
of controller therapy: ﬂuticasone propionate (FP), salmeterol
(SAL), ipratropium (IPR), ipratropium + albuterol (IPA), and
ﬂuticasone/salmeterol combination (FSC) was calculated for each
patient using Medication Possession Ratios (MPR), the mean
number of prescription ﬁlls in the year following diagnosis. Cor-
relations between controller therapy and albuterol use, outpa-
tient, and inpatient visits were assessed using Pearson correlation
coefﬁcients and Negative Binomial regression models controlling
for age, sex, and Hispanic ethnicity. RESULTS: The sample of
991 patients included 6.6% FP, 8.8% IPA, 3.6% IPR, 2.5% SAL,
8.1% FSC, and 77.5% non-controller. The sample was 51.9%
female, 24.9% estimated Hispanic ethnicity, and mean age was
68 years. Albuterol MPR was correlated with FP (r = 0.42,
p < 0.0001), IPA (r = 0.08, p = 0.007), IPR (r = 0.37, p <
0.0001), SAL (r = 0.12, p < 0.0001), and FSC (r = 0.33, p <
0.0001). No controllers were signiﬁcantly correlated with
outpatient visit use. No controllers were signiﬁcantly correlated
with albuterol MPR when controlling for sex, ethnicity, and
age. FSC MPR was the only controller that was negatively cor-
related with hospitalizations (-2.05, p = 0.04). CONCLUSION:
Patients with an initial diagnosis of COPD experienced less hos-
pitalizations with more FSC use during the ﬁrst year, suggesting
a duration-response relationship. Controller use was not signiﬁ-
cantly correlated with albuterol MPR or count of outpatient
visits after adjustment.
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OBJECTIVE: The 2007 Canadian Respiratory Disease Guide-
lines recommend that treatment be initiated with inhaled corti-
costeroids (ICS). An analysis of provincial drug claims data was
undertaken to determine the impact of Ontario’s restricted drug
access system relative to Alberta’s open public formulary on the
use of four types of medication to treat respiratory disease. These
consisted of low cost ICS and higher cost long-acting b2 agonists
(LABA), combination therapy ICS plus LABA (COMBO) and
leukotrienes (LTRA). METHODS: A retrospective 12-month
review of patients aged < 55 years who were treated under the
public and private payer systems in Ontario and Alberta were
analyzed for “ﬁrst use” of inhaled respiratory therapies. “First
use” was deﬁned as a patient who had no prior record in the
previous three years of any controller agent. Inter and intra
provincial utilization comparisons were undertaken and reported
as likelihood ratios (LR). RESULTS: Under the restricted Ontario
public formulary, ﬁrst use ICS was signiﬁcantly more likely over
LABA, COMBO and LTRA (LR = 1.9; 3.0 and 16.9: p < 0.001)
relative to private drug plans in the province. In contrast, there
was signiﬁcantly less ICS use over the more costly LABA in the
open Alberta public system (LR = 0.37; p < 0.001). Furthermore,
there was almost identical usage of ICS vs. COMBO and LTRA
between the Alberta public and private drug plans (LR = 0.91;
p = 0.057 and 1.56; p = 0.001). CONCLUSION: Formulary
restrictions that are in keeping with clinical practice guidelines
appear to be an effective method for promoting appropriate drug
use and containing formulary expenditures. However, the impact
of such restrictions on other health care resources such as hos-
pital admissions for poorly controlled respiratory disease is
unknown. Patient level research is needed to evaluate the total
impact of formulary restrictions on all aspects of the health care
system.
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ABSENCE OF CONTROLLER DRUG USE AMONG ASTHMATIC
PATIENTS AT RISK OF ASTHMA ATTACK
Vaidya V, Hong SH
University of Tennessee, Memphis,TN, USA
OBJECTIVE: Despite the recommendations from national guide-
lines, under-use of controller medications and overuse of quick
relief medications persists amongst asthmatics. The main objec-
tive of this study was to determine the effects of health insurance,
prescription drug insurance and availability of peak ﬂow meter
on controller drug therapy not being used by asthmatic patients.
METHODS: Data for this study came from 2004 Medical
Expenditure Panel Survey (MEPS).Study population included all
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